1 week Ago By Defense World Staff
Invesco Ltd. lowered its position in Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR – Free Report ) by 27.
4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 176,235 shares of the biotechnology company’s stock after selling 66,640 shares during the quarter. Invesco Ltd.
owned about 0.14% of Arrowhead Pharmaceuticals worth $3,313,000 as of its most recent filing with the Securities and Exchange Commission. Other hedge funds also recently made changes to their positions in the company.
Norges Bank acquired a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $38,622,000. Edgestream Partners L.P.
bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $2,264,000. Wealthfront Advisers LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $2,060,000. King Luther Capital Management Corp bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at about $1,447,000.
Finally, Pinion Investment Advisors LLC acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $1,410,000. Institutional investors own 62.61% of the company’s stock.
Wall Street Analyst Weigh In Several equities analysts have commented on ARWR shares. B. Riley reissued a “buy” rating and set a $38.
00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Chardan Capital reiterated a “buy” rating and set a $60.
00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Royal Bank of Canada restated an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th.
Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company’s stock.
According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $41.44.
Insider Buying and Selling at Arrowhead Pharmaceuticals In related news, CEO Christopher Richard Anzalone sold 133,333 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.
66. Following the transaction, the chief executive officer now directly owns 3,773,802 shares of the company’s stock, valued at approximately $64,230,110.04.
The trade was a 3.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website .
Insiders have sold a total of 275,880 shares of company stock valued at $4,034,037 in the last three months. 4.30% of the stock is currently owned by company insiders.
Arrowhead Pharmaceuticals Trading Down 0.7 % Shares of ARWR opened at $13.25 on Monday.
The business’s 50-day moving average price is $14.57 and its 200 day moving average price is $18.41.
The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.
27. The stock has a market capitalization of $1.82 billion, a P/E ratio of -2.
56 and a beta of 0.99. Arrowhead Pharmaceuticals, Inc.
has a 1-year low of $9.57 and a 1-year high of $30.41.
Arrowhead Pharmaceuticals ( NASDAQ:ARWR – Get Free Report ) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($0.
42) by ($0.97). Analysts expect that Arrowhead Pharmaceuticals, Inc.
will post -2.42 earnings per share for the current year. Arrowhead Pharmaceuticals Company Profile ( Free Report ) Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States.
The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. Recommended Stories Five stocks we like better than Arrowhead Pharmaceuticals Mastering Discipline: Overcoming Emotional Challenges In Trading Texas Instruments: Earnings Beat, Upbeat Guidance Fuel Recovery What Is WallStreetBets and What Stocks Are They Targeting? O’Reilly Automotive: An Anytime Buy for Buy-and-Hold Investors How to Know Which Cryptocurrency to Buy: A Guide for Investors Chipotle Mexican Grill Serves Smoking Hot Entry Point in Q2 Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc.
( NASDAQ:ARWR – Free Report ). Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
